Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.

Sarangarajan R. et al, (2020), J Racial Ethn Health Disparities

Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).

Grozinsky-Glasberg S. et al, (2020), Endocr Relat Cancer, 27, R345 - R355

Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells.

Lines KE. et al, (2020), Endocr Relat Cancer, 27, 163 - 174

Organizational Innovation for Developing New Medicines That Target Aging and Age-Related Conditions.

Ford GA. et al, (2020), J Gerontol A Biol Sci Med Sci, 75, 87 - 88

A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.

Fagan V. et al, (2019), J Med Chem, 62, 9008 - 9025

A genetics-led approach defines the drug target landscape of 30 immune-related traits.

Fang H. et al, (2019), Nat Genet, 51, 1082 - 1091

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X. et al, (2019), Prostate, 79, 1079 - 1089

ANGIOTENSIN 2 TYPE 2 RECEPTOR BLOCKADE IS A NOVEL TARGET FOR MURINE OSTEOARTHRITIS PAIN

von Loga IS. et al, (2019), OSTEOARTHRITIS AND CARTILAGE, 27, S420 - S421

An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.

D'Ascenzio M. et al, (2019), Angew Chem Int Ed Engl, 58, 1007 - 1012

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.

Vazquez-Rodriguez S. et al, (2019), Angew Chem Int Ed Engl, 58, 515 - 519

Donated chemical probes for open science.

Müller S. et al, (2018), Elife, 7

BROMODOMAIN INHIBITORS ARE POTENT EPIGENETIC REGULATORS OF CATABOLIC GENE EXPRESSION IN HUMAN OSTEOARTHRITIC CHONDROCYTES

de Andres MC. et al, (2018), OSTEOARTHRITIS AND CARTILAGE, 26, S154 - S154

Therapeutics discovery: From bench to first in-human trials.

Al-Hujaily EM. et al, (2018), Biomed Rep, 8, 275 - 282

Open innovation in neuroscience research and drug discovery.

Hunter AJ. et al, (2018), Brain Neurosci Adv, 2

The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.

Bradley AR. et al, (2017), Essays Biochem, 61, 495 - 503

Maximising value from a United Kingdom Biomedical Research Centre: study protocol.

Greenhalgh T. et al, (2017), Health Res Policy Syst, 15

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

Lines KE. et al, (2017), Oncogenesis, 6

Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Tumber A. et al, (2017), Cell Chem Biol, 24, 371 - 380

Establishing a reliable framework for harnessing the creative power of the scientific crowd.

Carter AJ. et al, (2017), PLoS Biol, 15

Assessing histone demethylase inhibitors in cells: lessons learned.

Hatch SB. et al, (2017), Epigenetics Chromatin, 10

Load More

1
2
3
4
5
6
7
...
»